Leanna Lui
Researcher/author in psychiatry at the University of Toronto
Data updated
Papers
Trials
Research Footprint
Leanna Lui appears in 8 tracked papers (2018–2022), most studied alongside Ketamine, Esketamine and MDMA, across Depressive Disorders, Suicidality and Treatment-Resistant Depression (TRD).
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Roger Ho.
Background & Research
Leanna M. W. Lui appears to be a psychiatry researcher based at the University of Toronto and has coauthored multiple papers on ketamine, esketamine, suicidality, and treatment-resistant depression. Her publications include systematic reviews and real-world analyses relevant to rapid-acting antidepressant and psychedelic-adjacent clinical research.
Key Impact
She co-authors systematic reviews and clinical studies on ketamine and esketamine for depression, suicidality, and related adverse effects, contributing to the evidence base in psychedelic and rapid-acting antidepressant research.
Collaboration Network
24 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Leanna Lui's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Leanna Lui is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →